Relmada acquires neurosteroid from Asarina
Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Relmada Therapeutics, Inc. has recently received a notice from the Nasdaq Stock Market indicating that the company’s security did not maintain a minimum bid price of $1 per share for the 30 ...
Relmada Therapeutics reports interim analysis of the Phase 3 Reliance II study for REL-1017 in major depressive disorder, indicating futility in meeting efficacy goals.
In a challenging year for Relmada Therapeutics (NASDAQ:RLMD), the company's stock has plummeted to a 52-week low, trading at just $0.34. According to InvestingPro data, the company maintains a strong ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback